ABSTRACT

Introduction:

Elevated transaminases has been frequently observed in pediatric emergency department admissions due to increasing utilization of routine laboratory packages. There are limited data about clinical features, underlying conditions and clinical course of these patients. This study aims to evaluate clinical characteristics, etiologies, recovery time and length of stay in hospital of children with elevated transaminases in pediatric emergency department.

Methods:

We included 1-month- 18-year-old children who were followed in observation unit of Pediatric Emergency Department of University of Health Sciences Turkey, Dr. Behçet Uz Pediatrics and Surgery Training and Research Hospital and had increased transaminases between 2016 January and 2017 January. Increased aspartate aminotransferase and alanine aminotransferase were defined as values above 60 U/L and 45 U/L. The clinical and laboratory data were obtained retrospectively from electronic medical records.

Results:

We included 89 patients. The median age was 36 months (1-216 months). The most common symptoms were vomiting (n=31), fever (n=27) and abdominal pain (n=25), the most frequent physical examination finding was dehydration (n=20). Etiologies were infections (40.5%), metabolic disorders (11.2%), drug induced liver injury (9.0%), hepatobiliary diseases (5.6%), others (9.0%) and unexplained in 24.7%. Transaminases were elevated under 5 times in 62.5%. N-acetylcystein and ursodeoxycolic acid were administered in 9.0% and 18.0%. The median recovery time was 5 days (1-61 days) and length of stay was 3.7±9.2 days. Recovery time and length of stay were not significantly different according to etiologies (p=0.107 and p=0.952).

Conclusion:

This study has indicated that mild elevation of transaminases is common in pediatric emergency department. Although most common reason is infections, it can be related to various conditions such as trauma and inherited metabolic disorders. Also, we have found that the recovery time is short and does not change according to etiologies. However, multi-center studies in a large population are still required to form algorithms for the assessment of elevated transaminases in pediatric emergency department .

Keywords: Emergency department, child, recovery time, elevated transaminase

References

Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci. 2014;11:925-35.

Sulava E, Bergin S, Long B, Koyfman A. Elevated Liver Enzymes: Emergency Department-Focused Management. J Emerg Med. 2017;52:654-67.

van Beek JH, de Moor MH, de Geus EJ, Lubke GH, Vink JM, et al. The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet. 2013;43:329-39.

Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36:973-7.

Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver ‘‘function’’ tests? Clin Pharmacol Ther. 2009;85:331-4.

Vajro P, Maddaluno S, Veropalumbo C. Persistent hypertransaminasemia in asymptomatic children: a stepwise approach. World J Gastroenterol. 2013;19:2740-51.

Korones DN, Brown MR, Palis J. ‘‘Liver function tests’’ are not always tests of liver function. Am J Hematol. 2001;66:46-8.

Iorio R, Sepe A, Giannattasio A, Cirillo F, Vegnente A. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol. 2005;40:820-6.

Nobili V, Reale A, Alisi A, Morino G, Trenta I, et al. Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Dig Liver Dis. 2009;41:749-52.

Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133:1814-20.

Park SH, Park HY, Kang JW, Park J, Shin KJ. Aminotransferase upper reference limits and the prevalence of elevated aminotransferases in the Korean adolescent population. J Pediatr Gastroenterol Nutr. 2012;55:668-72.

Çeltik C, HE, Kurşun ÖS, Bostancıoğlu M, İnan M, Öner N, et al. Çocukluk çağında serum transaminazlarını yükselten nedenler. Turk J Biochem. 2008;33:175-81.

Zhang J, Wang ZY, Zhang JP, Zhou H, Ding Z. Prevalence of Elevated Alanine Aminotransferase by Diagnostic Criterion, Age, and Gender among Adolescents. Gastroenterol Res Pract. 2020:p.4240380.

Serdaroğlu F, Koca T, Dereci S, Akçam M. The etiology of hypertransaminasemia in Turkish children. Bosn J Basic Med Sci. 2016;16:151-6.

Jang M, Oh MS, Oh SC, Kang KS. Distribution of Diseases Causing Liver Function Test Abnormality in Children and Natural Recovery Time of the Abnormal Liver Function. J Korean Med Sci. 2016;31:1784-9.

Morisco F, Pagliaro L, Caporaso N, Bianco E, Sagliocca L, et al. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis. 2008;40:585-98.

Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). JPGN. 2017;64:319-34.

Akelma AZ, Kütükoğlu I, Köksal T, Cizmeci MN, Kanburoglu MK, ve ark. Serum transaminase elevation in children with rotavirus gastroenteritis: seven years’ experience. Scand J Infect Dis. 2013;45:362-7.

Kovacs A, Chan L, Hotrakitya C, Overturf G, Portnoy B. Serum transaminase elevations in infants with rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1986;5:873-7.

Kucuk O, Ugras M, Bicer S, Col D, Giray T, ve ark. Hypertransaminasaemia in children with viral gastroenteritis. Infez Med. 2016;24:32-7.

Low EXS, Zheng Q, Chan E, Lim SG. Drug induced liver injury: East versus West - a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26:142-54.

Hunt CM, Yuen NA, Stirnadel-Farrant HA, Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol. 2014;70:519-26.

Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ. 1994;72:213-20.

Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther. 1999;13:979-96.

Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases: new targets, new therapies. Therap Adv Gastroenterol. 2018;11:1756284818787400.

Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55.

Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525-31.

Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, et al. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14:25-30.

Saleem AF, Abbas Q, Haque AU. Use of N-acetylcysteine in children with fulminant hepatic failure caused by acute viral hepatitis. J Coll Physicians Surg Pak. 2015;25:354-8.

Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013;57:1542-9.

Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2:003328.

Etiology, Laboratory and Clinical Course of Elevated Transaminases in Pediatric Emergency Department

ABSTRACT

References